This article relies largely or entirely on a single source. Relevant discussion may be found on the talk page. Please help improve this article by introducing citations to additional sources.Find sources: "5-MeO-AET" – news · newspapers · books · scholar · JSTOR (July 2022)
Legal status
Legal status
  • DE: NpSG (Industrial and scientific use only)
  • UK: Class A
  • 1-(5-methoxy-1H-indol-3-yl)butan-2-amine
CAS Number
CompTox Dashboard (EPA)
Chemical and physical data
Molar mass218.300 g·mol−1
3D model (JSmol)
Melting point201 to 203 °C (394 to 397 °F)
  • CCC(N)Cc2c[nH]c1ccc(cc12)OC
  • InChI=1S/C13H18N2O/c1-3-10(14)6-9-8-15-13-5-4-11(16-2)7-12(9)13/h4-5,7-8,10,15H,3,6,14H2,1-2H3 checkY
 ☒NcheckY (what is this?)  (verify)

5-Methoxy-alpha-ethyltryptamine (5-MeO-α-ET) is a psychoactive drug and member of the tryptamine chemical class. It produces psychedelic and stimulant effects.[1]


5-MeO-α-ET, when used recreationally, is usually taken orally at dosages of 50–75 mg.


5-MeO-α-ET produces entactogenic and stimulant effects that can last 4–6 hours. However, little information exists on the psychopharmacological effects of this compound, thus considerable variation with regard to dosage and effects can be expected.


There have been no reported deaths or hospitalizations from 5-MeO-α-ET, but its safety profile is unknown.


5-MeO-α-ET is unscheduled and uncontrolled in the United States, but possession and sales of 5-MeO-α-ET could be prosecuted under the Federal Analog Act because of its structural similarities to α-ET and α-MT.

See also


  1. ^ Deluca P, Davey Z, Corazza O, Di Furia L, Farre M, Flesland LH, et al. (December 2012). "Identifying emerging trends in recreational drug use; outcomes from the Psychonaut Web Mapping Project". Progress in Neuro-Psychopharmacology & Biological Psychiatry. Elsevier BV. 39 (2): 221–226. doi:10.1016/j.pnpbp.2012.07.011. PMID 22841965. S2CID 22296279.